CLINICAL_TRIALS
withdrawal
· 2009-02-04
Clinical Trial Update: Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.) [Phase 2]
Summary
A Phase 2 open-label trial evaluating anecortave acetate (15 mg) for retinal vein occlusion has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Manhattan Eye, Ear & Throat Hospital | Conditions: Retinal Vein Occlusion | Phase 2 | Status: WITHDRAWN